Findings

What do systematic reviews say?

22 questions · 22 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 36.4%GRADE not reported 0 · 0%Very low 10 · 45.5%Low 4 · 18.2%Moderate 0 · 0%High 0 · 0%

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
RR 2 [1.47, 2.72]
1 study · 129 participants
Very low

Tramadol vs paracetamol

Number of participants experiencing any serious adverse events · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found